Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature.
Anticancer Res
; 36(6): 2975-81, 2016 Jun.
Article
en En
| MEDLINE
| ID: mdl-27272813
ABSTRACT
BACKGROUND:
Circulating tumor cells have been described in prostate cancer patients at diagnosis and in the metastatic phase but little is known on their role at biochemical PSA recurrence. PATIENTS ANDMETHODS:
Patients radically cured with either prostatectomy or radiotherapy were sequentially included at PSA recurrence. The presence of CTCs was evaluated by the CellSearch system.RESULTS:
Twenty-nine patients were accrued at PSA recurrence. Median PSA at recurrence was 7.2 ng/ml (range=3.86-51.0 ng/ml). The median time to PSA progression was 4.66 years (range=0.1-16 years). CTCs were detected in one patient (3%) with low numbers (1 CTC/7.5 ml).CONCLUSION:
In patients radically cured for prostate cancer at biochemical recurrence, CTCs are detected at very low levels in a minority of patients. Further studies are required to investigate alternative methods of CTC detection and the possible role of the bone marrow pre-metastatic niche at biochemical recurrence.Palabras clave
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Antígeno Prostático Específico
/
Células Neoplásicas Circulantes
Tipo de estudio:
Observational_studies
Idioma:
En
Revista:
Anticancer Res
Año:
2016
Tipo del documento:
Article